CD274 and Merkel cell skin cancer: The Immune Checkpoint Inhibitors (ICIs), anti-PD-L1 avelumab and anti-PD-1 pembrolizumab, have been recently approved as first-line treatment in metastatic MCC, although only a minority of patients exhibit long-term response (7, 8).